A carregar...
Interrupting Anticoagulation in Patients With Nonvalvular Atrial Fibrillation
Three target-specific oral anticoagulants (TSOACs)—dabigatran, rivaroxaban, and apixaban—have been approved by the FDA to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; however, no agents are currently approved to reverse the anticoagulant effects o...
Na minha lista:
| Publicado no: | P T |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MediMedia USA, Inc.
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4264672/ https://ncbi.nlm.nih.gov/pubmed/25516695 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|